Outcome of Board Meeting held on 30th May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ishita Drugs & Industries Ltd's Board approved the audited financial results for the quarter and year ended 31st March 2026. The company reported profit before tax of Rs. 108 lakhs compared to Rs. 115.51 lakhs in the previous year, indicating a slight decline. Total assets decreased from Rs. 1,629.59 lakhs to Rs. 1,260.37 lakhs, while total equity increased from Rs. 1,078.96 lakhs to Rs. 1,156.81 lakhs. Cash flow from operations improved to Rs. 391.93 lakhs from Rs. 363.71 lakhs. The statutory auditors issued an unmodified (clean) opinion on the financial statements. The Board also approved the Directors' Report, Corporate Governance report, and Notice for the 33rd AGM, and re-appointed internal auditors for 2026-27.
The clean audit opinion with unmodified results is positive for shareholders, indicating no material concerns. However, the decline in profit before tax and total assets warrants monitoring. The significant reduction in borrowings (from Rs. 390.29 lakhs to Rs. 8.18 lakhs) shows improved financial health.